Quick Answer
Boundless Bio, Inc. reported Net Income of -$58.20 million for fiscal year 2025.
Boundless Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$58.20M +11.0% |
-$65.36M -32.2% |
-$49.43M | — |
| Diluted EPS | -$2.60 +32.5% |
-$3.85 +90.5% |
-$40.65 | — |
| Total Assets | $157.06M -23.9% |
$206.41M +58.9% |
$129.89M | — |
| Cash and Equivalents | $17.87M -32.8% |
$26.59M +12.2% |
$23.71M | — |
| Stockholders Equity | $98.65M -34.5% |
$150.64M +218.5% |
-$127.08M -55.6% |
-$81.70M |
| R&D Expense | $44.84M -18.9% |
$55.27M +29.6% |
$42.64M | — |
| Operating Income | -$63.55M +13.3% |
-$73.27M -33.7% |
-$54.80M | — |
| Shares Outstanding | 22.41M +0.5% |
22.30M +1786759.0% |
1,248 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$13.88M | +15.9% | +11.5% |
| Diluted EPS | September 30, 2025 | -$0.62 | +16.2% | +11.4% |
| Total Assets | September 30, 2025 | $168.72M | -3.6% | -6.0% |
| Cash and Equivalents | September 30, 2025 | $14.98M | -62.7% | +1.9% |
| Stockholders Equity | September 30, 2025 | $110.17M | -33.3% | -10.2% |
| R&D Expense | September 30, 2025 | $10.67M | -24.2% | -12.6% |
| Operating Income | September 30, 2025 | -$15.15M | +19.1% | +11.2% |
| Shares Outstanding | September 30, 2025 | 22.39M | +0.6% | +0.0% |
- Boundless Bio, Inc. reported Net Income of -$58.20 million for fiscal year 2025.
- Boundless Bio, Inc. showed an increase of +11.0% in Net Income compared to the prior fiscal year.
- Boundless Bio, Inc. reported Diluted EPS of $2.60 per share (loss) for fiscal year 2025.
- Boundless Bio, Inc. showed an increase of +32.5% in Diluted EPS compared to the prior fiscal year.
- Boundless Bio, Inc. reported Total Assets of $157.06 million for fiscal year 2025.
- Boundless Bio, Inc. showed a decrease of -23.9% in Total Assets compared to the prior fiscal year.
- Boundless Bio, Inc. reported Cash and Equivalents of $17.87 million for fiscal year 2025.
- Boundless Bio, Inc. showed a decrease of -32.8% in Cash and Equivalents compared to the prior fiscal year.
- Boundless Bio, Inc. reported Stockholders Equity of $98.65 million for fiscal year 2025.
- Boundless Bio, Inc. showed a decrease of -34.5% in Stockholders Equity compared to the prior fiscal year.
- Boundless Bio, Inc. reported R&D Expense of $44.84 million for fiscal year 2025.
- Boundless Bio, Inc. showed a decrease of -18.9% in R&D Expense compared to the prior fiscal year.
- Boundless Bio, Inc. reported Operating Income of -$63.55 million for fiscal year 2025.
- Boundless Bio, Inc. showed an increase of +13.3% in Operating Income compared to the prior fiscal year.
- Boundless Bio, Inc. reported Shares Outstanding of 22.41 million shares for fiscal year 2025.
- Boundless Bio, Inc. showed an increase of +0.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: